Ovid Therapeutics
Ovid Therapeutics develops small molecule therapies for epilepsies and brain conditions, with a focus on reducing seizures and improving safety and tolerability.
Ovid Therapeutics Services
Ovid Therapeutics focuses on developing small molecule therapies aimed at reducing seizures and improving safety and tolerability for patients. The company specializes in treating epilepsies and brain conditions, leveraging their expertise to create impactful treatments. Their services include cutting-edge research, clinical trials, and collaborations with esteemed institutions. By managing a comprehensive pipeline of therapeutic candidates and ensuring stringent safety measures, Ovid Therapeutics is committed to advancing the medical field in their niche areas.
Ovid Therapeutics Pipeline
Ovid Therapeutics has an advanced therapeutic pipeline including several key candidates: Soticlestat, OV888, OV329, and OV350. Soticlestat, a cholesterol 24-hydroxylase inhibitor, is aimed at treating Dravet syndrome and Lennox-Gastaut syndrome and is currently in Phase 3 trials. OV888 is a selective ROCK2 inhibitor developed in collaboration with Graviton Biosciences. OV329, a next-generation GABA-aminotransferase inhibitor, is in a Phase 1 study for epilepsies. OV350, a KCC2 transporter activator, is optimized for both intravenous and oral formulations to treat resistant epilepsies and other neuropathologies.
Ovid Therapeutics Collaborations
Ovid Therapeutics collaborates with notable organizations including Graviton Biosciences, AstraZeneca, and Takeda to enhance their research and development capabilities. They also have an ongoing collaboration with Columbia University Irving Medical Center focusing on genetic-based therapies. Through these strategic partnerships, Ovid Therapeutics aims to accelerate the development of treatments and improve patient outcomes in the field of epilepsies and brain conditions.
Ovid Therapeutics History
Founded in April 2014, Ovid Therapeutics has established itself as a leader in developing innovative treatments for epilepsies and brain conditions. The company is headquartered at Hudson Commons, 441 9th Avenue, New York, NY, with lab space located at Tufts Launchpad BioLabs in Boston, MA. One of its key achievements includes the development and sale of Soticlestat, a late-stage clinical asset, to Takeda. Ovid Therapeutics continues to drive forward with critical research and development initiatives, maintaining a strong commitment to patient advocacy and diverse workplace culture.